Search Results - "Higham, Robert C"

Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States by Armstrong, April, Young, Melodie, Seal, Melissa S, Higham, Robert C, Greiling, Teri

“…Topical treatments are the foundation for patients with psoriasis; however, adherence can be limited by patient preferences and treatment burden. The Harris…”
Get full text

Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States by Greiling, Teri, Young, Melodie, Seal, Melissa S., Higham, Robert C., Armstrong, April

“…Introduction A survey was conducted by The Harris Poll on behalf of Arcutis Biotherapeutics in the USA to understand perspectives and burden of patients with…”
Get full text

Manifestations and Management of Difficult-to-Treat Psoriasis by Aldredge, Lakshi M, Higham, Robert C

“…ABSTRACTPsoriasis is a common, immune-mediated skin disorder that can manifest as multiple clinical phenotypes. Although psoriasis affecting the scalp, face,…”
Get full text

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials by Lebwohl, Mark G, Kircik, Leon H, Moore, Angela Y, Stein Gold, Linda, Draelos, Zoe D, Gooderham, Melinda J, Papp, Kim A, Bagel, Jerry, Bhatia, Neal, Del Rosso, James Q, Ferris, Laura K, Green, Lawrence J, Hebert, Adelaide A, Jones, Terry, Kempers, Steven E, Pariser, David M, Yamauchi, Paul S, Zirwas, Matthew, Albrecht, Lorne, Devani, Alim R, Lomaga, Mark, Feng, Amy, Snyder, Scott, Burnett, Patrick, Higham, Robert C, Berk, David R

“…IMPORTANCE: Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of…”
Get full text

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies by Thurston, Archie W., Osborne, David W., Snyder, Scott, Higham, Robert C., Burnett, Patrick, Berk, David R.

“…Background Most patients with chronic plaque psoriasis receive topical treatment; however, available options lack a balance of efficacy with long-term safety…”
Get full text

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study by Kircik, Leon H, Alonso-Llamazares, Javier, Bhatia, Neal, Bukhalo, Michael, Devani, Alim R, Draelos, Zoe D, DuBois, Janet, Gooderham, Melinda J, Kempers, Steven E, Lain, Edward , Lee, Mark, Moore, Angela, Murrell, Dedee F, Papp, Kim A, Pariser, David M, Sinclair, Rodney , Zirwas, Matthew, Burnett, Patrick, Higham, Robert C, Krupa, David, Berk, David R

“…BACKGROUNDScalp psoriasis affects most patients with psoriasis, but it can be difficult to treat. OBJECTIVESTo evaluate the efficacy and safety of once-daily…”
Get full text

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial by Zirwas, Matthew J, Draelos, Zoe D, DuBois, Janet, Kircik, Leon H, Moore, Angela Y, Stein Gold, Linda, Alonso-Llamazares, Javier, Bukhalo, Michael, Bruce, Suzanne, Eads, Kimmie, Green, Lawrence J, Guenthner, Scott T, Ferris, Laura K, Forman, Seth B, Kempers, Steven E, Lain, Edward, Lynde, Charles W, Pariser, David M, Toth, Darryl P, Yamauchi, Paul S, Higham, Robert C, Krupa, David, Burnett, Patrick, Berk, David R

“…Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. To assess safety and efficacy of roflumilast foam, 0.3%, in…”
Get more information

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial by Draelos, Zoe D, Adam, David N, Hong, H Chih-Ho, Lebwohl, Mark G, Lynde, Charles W, Nahm, Walter K, Papp, Kim A, Pariser, David M, Stein Gold, Linda, Stewart, Daniel, Higham, Robert C, Berk, David R, Krupa, David, Burnett, Patrick

“…This post hoc analysis evaluated efficacy and safety of roflumilast cream in patients with psoriasis involving the face/neck or intertriginous areas from a…”
Get full text

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial by Stein Gold, Linda, Alonso-Llamazares, Javier, Draelos, Zoe D., Gooderham, Melinda J., Kempers, Steven E., Kircik, Leon H., Lebwohl, Mark G., Papp, Kim A., Pariser, David M., Toth, Darryl P., Yosipovitch, Gil, Higham, Robert C., Feng, Amy, Berk, David R.

“…Background Itch is the most bothersome symptom reported by patients with psoriasis. Safe and effective treatments for psoriasis that also address itch are…”
Get full text

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score by Papp, Kim A., Lebwohl, Mark G., Kircik, Leon H., Pariser, David M., Strober, Bruce, Krueger, Gerald G., Berk, David R., Navale, Lynn, Higham, Robert C.

“…The Psoriasis Area and Severity Index (PASI) is the most widely used clinical measure in clinical trials to assess disease severity of plaque psoriasis…”
Get full text

505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials by Eichenfield, Lawrence F, Boguniewicz, Mark, Simpson, Eric L, Blauvelt, Andrew, Gooderham, Melinda, Lain, Edward, Chu, David H, Higham, Robert C

Get full text

53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis by Simpson, Eric, Boguniewicz, Mark, Eichenfield, Lawrence, Gonzales, Mercedes E., Hebert, Adelaide A., Prajapati, Vimal H., Gooderham, Melinda, Krupa, David, Chu, David H., Higham, Robert C., Berk, David R.

Get full text

641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis by Simpson, Eric, Boguniewicz, Mark, Eichenfield, Lawrence, Gonzales, Mercedes E, Hebert, Adelaide A, Prajapati, Vimal H, Gooderham, Melinda, Krupa, David, Chu, David H, Higham, Robert C, Berk, David R

Get full text

Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema by Draelos, Zoe Diana, Higham, Robert C, Osborne, David W, Seal, Melissa S, Burnett, Patrick, Berk, David R

“…Inflammatory dermatologic conditions suitable for topical treatments benefit from a hydrating vehicle that improves the skin barrier without irritation. This…”
Get more information

33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area by Gold, Linda Stein, Bagel, Jerry, Del Rosso, James, Green, Lawrence J., Lebwohl, Mark, Kircik, Leon H., Feng, Amy, Snyder, Scott, Higham, Robert C., Burnett, Patrick, Berk, David R.

Get full text

Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States by Greiling, Teri, Young, Melodie, Higham, Robert C, Armstrong, April W

Get full text

28588 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study by Zirwas, Matthew, Draelos, Zoe D., DuBois, Janet, Kircik, Leon, Moore, Angela, Gold, Linda Stein, Higham, Robert C., Navale, Lynn, Burnett, Patrick, Berk, David R.

Get full text

27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor by Papp, Kim A., Lebwohl, Mark G., Kircik, Leon, Pariser, David, Strober, Bruce, Krueger, Gerald, Berk, David R., Navale, Lynn, Higham, Robert C.

Get full text

638 - Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial by Simpson, Eric L, Eichenfield, Lawrence F, Papp, Kim A, Forman, Seth, Hebert, Adelaide A, Gonzalez, Mercedes E, Gooderham, Melinda, Chih-ho Hong, H, Prajapati, Vimal H, Guttman, Emma, Silverberg, Jonathan, Seal, Melissa, Krupa, David, Burnett, Patrick, Synder, Scott, Chu, David H, Higham, Robert C, Berk, David R

Get full text

640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis by Bunick, Christopher G, Bhatia, Neal, Del Rosso, James, Draelos, Zoe D, Eichenfield, Lawrence F, Kircik, Leon H, Lebwohl, Mark G, Gooderham, Melinda, Green, Lawrence J, Hebert, Adelaide A, Vender, Ronald B, Zirwas, Matthew, Simpson, Eric L, Gold, Linda Stein, Seal, Melissa, Snyder, Scott, Osborne, David W, Burnett, Patrick, Higham, Robert C, Chu, David H, Berk, David R

Get full text